Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Non Operating Income: 2020-2024

Historic Non Operating Income for Monte Rosa Therapeutics (GLUE) over the last 5 years, with Dec 2024 value amounting to $11.0 million.

  • Monte Rosa Therapeutics' Non Operating Income fell 0.80% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.4 million, marking a year-over-year increase of 34.78%. This contributed to the annual value of $11.0 million for FY2024, which is 32.36% up from last year.
  • Latest data reveals that Monte Rosa Therapeutics reported Non Operating Income of $11.0 million as of FY2024, which was up 32.36% from $8.3 million recorded in FY2023.
  • Monte Rosa Therapeutics' Non Operating Income's 5-year high stood at $11.0 million during FY2024, with a 5-year trough of -$7.9 million in FY2020.
  • For the 3-year period, Monte Rosa Therapeutics' Non Operating Income averaged around $7.7 million, with its median value being $8.3 million (2023).
  • Data for Monte Rosa Therapeutics' Non Operating Income shows a peak YoY skyrocketed of 460.87% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Monte Rosa Therapeutics' Non Operating Income stood at -$7.9 million in 2020, then skyrocketed by 86.33% to -$1.1 million in 2021, then skyrocketed by 460.87% to $3.9 million in 2022, then skyrocketed by 113.67% to $8.3 million in 2023, then surged by 32.36% to $11.0 million in 2024.